Peptide

Teduglutide

Also known as

Gattex · Revestive · GLP-2 analog

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A GLP-2 peptide sold as Gattex/Revestive for short-bowel syndrome, helping the remaining intestine absorb more food and fluid.
Patient versus biohacker context	These patient experiences concern very little remaining bowel and IV support. They do not establish gut-repair benefit in an intact intestine; GLP-2 is different from weight-loss GLP-1 drugs.

Notes

Teduglutide, sold as Gattex or Revestive, is a GLP-2 peptide used for short-bowel syndrome. People with very little bowel remaining describe less dependence on IV nutrition or fluids, sometimes alongside troublesome gut symptoms. Biohacking interest in gut repair reaches beyond those patient experiences; it does not establish the same benefits in an otherwise intact intestine.

Helping the remaining bowel absorb more. GLP-2 is a gut signal. Teduglutide imitates it, supporting the intestine's absorbing surface. Short-bowel syndrome leaves too little working bowel to absorb enough food or fluid, creating dependence on IV support. DailyMed GATTEX prescribing information (Official context · Accessed 2026-09-30)

GLP-2 is different from weight-loss GLP-1 drugs. A peptide-forum discussion explores intestinal repair, malabsorption and 'leaky gut,' while questioning growth-related risks. It asks whether anyone has tried these drugs; it is not a healthy-user treatment log. Gattex/Revestive patient experiences concern a daily injection, not a GLP-1 appetite-suppression stack. Glucagon-like peptide 2 analogs and receptor agonists (Community opinion · Accessed 2026-09-30) · Long-term Revestive/Gattex experience request (Community discussion · Accessed 2026-09-30)

Source context — DailyMed GATTEX prescribing information: Prescription SBS context only; does not validate general gut repair or gray-market preparations. Formal values never supplied as firsthand community measurements. Preparation instructions read incidentally but not reproduced.

Source context — Glucagon-like peptide 2 analogs and receptor agonists: Mechanistic discussion and quoted papers, not firsthand dosing or outcomes. Claims about broad leaky-gut use remain speculation. Other GLP-2 analogs' longer half-lives are not teduglutide values. Sourcing requests excluded.

Source context — Long-term Revestive/Gattex experience request: OP is considering therapy, not reporting success. Opened page omitted newer September 2026 replies that appeared in search extraction; those newer replies are not used. Historical quoted price not a current price.

What people notice

Less IV support	Some patients describe less dependence on IV nutrition or fluids and slower diarrhea. One still returns to IV nutrition when levels fall; improvement need not mean permanent independence.
Improvement with gut symptoms	A major-resection patient described much better symptom control with gas and bloating. Other reviews include reduced support alongside pain or concerning rapid weight gain and breathlessness.

Notes

Less time tied to IV support. In a transplant discussion, the original poster later reports being nearly off total parenteral nutrition (TPN), with slower diarrhea and less anti-diarrhea medication. A separate commenter describes being off TPN most of the time, but needing a month back on when nutrition levels fall. Improvement need not mean permanent independence. Short Gut & TPN (Community discussion · Accessed 2026-09-30)

Better symptom control can coexist with gas. One person after major bowel resection describes a major improvement, with bloating and gas as the main downside. They also had lifelong inability to burp, so their gurgling and bloating cannot be assigned entirely to the injection. A slightly unusual R-CPD story (Personal report · Accessed 2026-09-30)

Benefits and side effects can arrive together. On Drugs.com, one reviewer reports reduced TPN and IV fluids alongside bloating and chest/back pain. Another reports rapid weight gain, breathlessness and a larger stoma after one week. These are concerning experiences, not proof that rapid weight gain represents nutritional recovery. Gattex user reviews (Personal report · Accessed 2026-09-30)

Source context — Short Gut & TPN: Distinct users within one thread, not duplicate corroboration. Severe disease, surgery and continuing nutrition care confound attribution. TPN duration before weaning is not a measured teduglutide onset. Relative reply dates not converted to calendar dates; prices not reproduced as current.

Source context — A slightly unusual R-CPD story: One uncontrolled anonymous story; anatomy and no-burp condition confound symptoms. Not an independently verified clinical outcome or a healthy-user biohacking report.

Source context — Gattex user reviews: Self-selected, site-edited unverified reviews; no doses, medical records or denominator. Two Cro... entries may be one user and are not counted as independent. Caregiver events after discontinuation do not establish causation. Ratings are not success rates.

Doses people talk about

Circulated label amount	0.05 mg/kg once daily under the skin is repeated from short-bowel prescribing. It is weight-based, not 0.05 mg total, and is not a separately established biohacker range.
Patient accounts	Most stories omit the amount, though daily injections are described. They do not establish a low-dose gut-repair band, oral alternative or preferred meal slot.

Notes

0.05 mg/kg/day: a circulated label figure. BioHack Track repeats this under-the-skin amount, marked 'per label.' It means a weight-based daily administration, not 0.05 mg total. Its origin is short-bowel prescribing, not an independently demonstrated biohacker dose range. BioHack Track Teduglutide compound library (Community guide · Accessed 2026-09-30)

The dose figure belongs to prescription SBS care. The US label specifies 0.05 mg/kg once daily under the skin, or 0.025 mg/kg once daily for specified kidney impairment. These clinical amounts do not establish equivalence for unverified vials. DailyMed GATTEX prescribing information (Official context · Accessed 2026-09-30)

Patient stories usually omit the amount. The Revestive thread describes daily injections; the symptom-control account gives no dose. Neither supplies a separate low-dose gut-repair band, a preferred meal slot or an oral alternative. Long-term Revestive/Gattex experience request (Community discussion · Accessed 2026-09-30) · A slightly unusual R-CPD story (Personal report · Accessed 2026-09-30)

Source context — BioHack Track Teduglutide compound library: Commercial app library, no first-person experience. Dose and half-life are borrowed clinical context, not user-derived measurements. Contradictory approval text, inaccurate boxed-warning wording and storage advice prevent treating this as authoritative. Article only attributes the circulated figures, with origin stated.

Half-life, onset & duration

Felt onset	One review described improvement after a couple of weeks, then further change after dietary adjustments. It is one person's timeline, not a guaranteed start.
Felt duration	No dependable one-injection symptom window or benefit duration after stopping is established.
Half-life	Formal values differ: about 1.3 hours in short-bowel patients and 2 hours in healthy subjects; a separate SBS model estimates 1.47 hours. These measure blood decline, not intestinal benefit duration.

Notes

One review describes a couple of weeks. An August 2021 Drugs.com reviewer noticed improvement on that timescale, then further improvement after dietary changes. Dose is unstated. This is an individual timeline, not a guaranteed starting point or proof that every change came from teduglutide. Gattex user reviews (Personal report · Accessed 2026-09-30)

No dependable per-injection effect window. The no-burp account describes ongoing symptom control without an hourly onset or offset. Long-term improvement does not tell us how many hours one injection feels active, or how long benefits survive stopping. A slightly unusual R-CPD story (Personal report · Accessed 2026-09-30)

1.3, 1.47 and 2 hours have different contexts. The label gives about 1.3 hours in SBS and 2 hours in healthy subjects. An adult/pediatric SBS model estimates 1.47 hours. These describe falling blood concentrations, not how long intestinal benefit feels noticeable. DailyMed GATTEX prescribing information (Official context · Accessed 2026-09-30) · Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric SBS (Official context · Accessed 2026-09-30)

Source context — Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric SBS: Population model, not felt duration or a universal adult-only constant. Industry-linked trial analysis. No inference of washout or DIY dosing.

Cycles people discuss

Long-term therapy	Daily long-term treatment and four or five years of use appear in patient accounts. They do not establish a weeks-on/weeks-off cycle or a break preserving benefits.

Notes

Years of treatment, rather than a short peptide cycle. A Gattex user in the cancer discussion reports four or five years of use and credits it with helping them leave TPN. The Revestive poster was offered daily long-term therapy. Neither account establishes a weeks-on/weeks-off routine or a break that preserves benefits. Gattex and cancer question (Community discussion · Accessed 2026-09-30) · Long-term Revestive/Gattex experience request (Community discussion · Accessed 2026-09-30)

Source context — Gattex and cancer question: No verified clinical records. The reply's annual-colonoscopy rule and guarantee-like confidence in detecting cancer are not adopted; label schedules vary by patient. Gallbladder attribution is the commenter's speculation, not causal evidence.

Stacks

Nutrition care	IV nutrition/fluids, diet and other short-bowel care are the actual co-treatment context. No specific biohacker peptide combination is established by these accounts.

Notes

Clinical nutrition care: IV nutrition and fluids, diet adjustments and other short-bowel care are the relevant combined-treatment context. Patient reports do not establish a biohacker peptide stack. [community]

Watch for

Absorption and growth risks	The label flags fluid overload, bowel/stoma blockage, gallbladder or pancreatic disease and abnormal tissue growth, including polyp surveillance. Stopping can disturb fluid and salt balance.
Medicines and serious symptoms	Oral medicines may be absorbed more strongly. Severe pain, vomiting or breathing difficulty needs medical assessment; pregnancy evidence is limited and breastfeeding is not recommended in the label.
Unverified products	Prescription patient stories cannot verify an unknown vial's identity, quality or safety. Injection-site reactions and uncertain long-term effects remain concerns.

Notes

More absorption can create new problems. The label warns about fluid overload, bowel or stoma blockage, gallbladder and pancreatic disease, and abnormal tissue growth. Polyp surveillance matters. Stopping can disturb fluid and salt balance; severe pain, vomiting or breathing difficulty needs medical assessment. DailyMed GATTEX prescribing information (Official context · Accessed 2026-09-30)

Other oral drugs may be absorbed more strongly. The label flags medicines such as benzodiazepines. Pregnancy evidence is limited; breastfeeding is not recommended. Injection-site reactions also occur. DailyMed GATTEX prescribing information (Official context · Accessed 2026-09-30)

A named peptide is not a verified product. Community cautions include uncertain long-term effects of gray-market preparations and redness, itching, lumps or bruising after injections. Several compounds used together make side effects harder to attribute. Prescription patient stories cannot establish an unknown product's identity, quality or safety.

Full notes

What Teduglutide actually does

Helping the remaining bowel absorb more. GLP-2 is a gut signal. Teduglutide imitates it, supporting the intestine's absorbing surface. Short-bowel syndrome leaves too little working bowel to absorb enough food or fluid, creating dependence on IV support. Official context
GLP-2 is different from weight-loss GLP-1 drugs. A peptide-forum discussion explores intestinal repair, malabsorption and 'leaky gut,' while questioning growth-related risks. It asks whether anyone has tried these drugs; it is not a healthy-user treatment log. Gattex/Revestive patient experiences concern a daily injection, not a GLP-1 appetite-suppression stack. Reddit r/Peptides Reddit r/ostomy

What people hope to gain

Less time tied to IV support. In a transplant discussion, the original poster later reports being nearly off total parenteral nutrition (TPN), with slower diarrhea and less anti-diarrhea medication. A separate commenter describes being off TPN most of the time, but needing a month back on when nutrition levels fall. Improvement need not mean permanent independence. Reddit r/transplant
Better symptom control can coexist with gas. One person after major bowel resection describes a major improvement, with bloating and gas as the main downside. They also had lifelong inability to burp, so their gurgling and bloating cannot be assigned entirely to the injection. Personal report

Doses people discuss

0.05 mg/kg/day: a circulated label figure. BioHack Track repeats this under-the-skin amount, marked 'per label.' It means a weight-based daily administration, not 0.05 mg total. Its origin is short-bowel prescribing, not an independently demonstrated biohacker dose range. Community guide
Patient stories usually omit the amount. The Revestive thread describes daily injections; the symptom-control account gives no dose. Neither supplies a separate low-dose gut-repair band, a preferred meal slot or an oral alternative. Reddit r/ostomy Personal report

Half-life: the circulating number

About 2 hours is a tracker assumption. BioHack Track uses that figure to model blood levels. It borrows clinical pharmacology; it does not measure a user's symptom relief or intestinal adaptation. Population-specific formal values appear below. Community guide

When changes first appear

One review describes a couple of weeks. An August 2021 Drugs.com reviewer noticed improvement on that timescale, then further improvement after dietary changes. Dose is unstated. This is an individual timeline, not a guaranteed starting point or proof that every change came from teduglutide. Personal report

How long a benefit lasts

No dependable per-injection effect window. The no-burp account describes ongoing symptom control without an hourly onset or offset. Long-term improvement does not tell us how many hours one injection feels active, or how long benefits survive stopping. Personal report

Long-term use and breaks

Years of treatment, rather than a short peptide cycle. A Gattex user in the cancer discussion reports four or five years of use and credits it with helping them leave TPN. The Revestive poster was offered daily long-term therapy. Neither account establishes a weeks-on/weeks-off routine or a break that preserves benefits. Reddit r/ostomy Reddit r/ostomy

Separately: clinical dose and blood timing

The dose figure belongs to prescription SBS care. The US label specifies 0.05 mg/kg once daily under the skin, or 0.025 mg/kg once daily for specified kidney impairment. These clinical amounts do not establish equivalence for unverified vials. Official context
1.3, 1.47 and 2 hours have different contexts. The label gives about 1.3 hours in SBS and 2 hours in healthy subjects. An adult/pediatric SBS model estimates 1.47 hours. These describe falling blood concentrations, not how long intestinal benefit feels noticeable. Official context Official context

Good to know

More absorption can create new problems. The label warns about fluid overload, bowel or stoma blockage, gallbladder and pancreatic disease, and abnormal tissue growth. Polyp surveillance matters. Stopping can disturb fluid and salt balance; severe pain, vomiting or breathing difficulty needs medical assessment. Official context
Other oral drugs may be absorbed more strongly. The label flags medicines such as benzodiazepines. Pregnancy evidence is limited; breastfeeding is not recommended. Injection-site reactions also occur. Official context
A named peptide is not a verified product. Community cautions include uncertain long-term effects of gray-market preparations and redness, itching, lumps or bruising after injections. Several compounds used together make side effects harder to attribute. Prescription patient stories cannot establish an unknown product's identity, quality or safety. Community

What living with it can involve

Less IV support can still mean ongoing nutrition care. The transplant commenter with about 70 cm of small intestine describes occasional TPN returns and repeated annual insurance approval battles. Their anatomy includes earlier gastric-bypass surgery. That account adds practical context to 'off TPN' without predicting another person's outcome or today's price. Reddit r/transplant
Benefits and side effects can arrive together. On Drugs.com, one reviewer reports reduced TPN and IV fluids alongside bloating and chest/back pain. Another reports rapid weight gain, breathlessness and a larger stoma after one week. These are concerning experiences, not proof that rapid weight gain represents nutritional recovery. Personal report
A negative caregiver account also matters. An August 2026 review describes pain throughout the child's use, then blood clots and blood in stool after stopping. The sequence cannot establish that teduglutide or withdrawal caused those events; the rest of the child's medical history is unstated. Personal report
Growth concerns are debated, not resolved by testimonials. The peptide-forum author emphasizes normal gut renewal; a reply worries about cancer. In the patient thread, a long-term user weighs benefit against that concern and describes a gallbladder infection they think was more likely related to TPN. Neither interpretation proves the cause or removes monitoring needs. Reddit r/Peptides Reddit r/ostomy